New Partnership Introduces Advanced Drug Residue Testing Technology to Canadian Market

The strategic partnership between Taizhou Kaimi Biotech and Scenesafe Trauma Scene Remediation introduces the Unow™ Drug Residue Test Device to the Canadian market, offering laboratory-grade identification of trace amounts of hazardous substances including opioids, fentanyl, and methamphetamine. This portable testing solution enables swift detection capabilities that serve multiple critical sectors across the country, addressing growing concerns about drug contamination in various environments.

The technology's applications span law enforcement investigations, healthcare facility sterilization, remediation team validation processes, and residential and commercial property safety assurance. Otis Zhao, President and Founder of Taizhou Kaimi Biotech, emphasized the technology's community protection potential, noting that the partnership with Scenesafe ensures the solution meets specific Canadian market requirements. The collaboration combines Taizhou Kaimi Biotech's biotech innovation expertise with Scenesafe's comprehensive understanding of Canadian safety protocols to establish new standards in drug residue detection and remediation.

Hang Ai, Founder of Scenesafe, highlighted the device's significance in addressing drug contamination risks for first responders, families, and businesses across Canada. The Unow™ Drug Residue Test Device represents a substantial advancement in portable diagnostic technologies and public safety solutions, scheduled for availability to Canadian clients in the second quarter of 2025. This timing aligns with increasing concerns about substance contamination in various settings, from public spaces to private residences. The technology's introduction comes at a critical moment when reliable, rapid detection methods are increasingly necessary for public health and safety initiatives nationwide.

Pre-orders for the device are anticipated to open soon, providing Canadian organizations and agencies with early access to this innovative testing solution. The partnership between these specialized companies demonstrates how targeted collaborations can address specific national safety needs while leveraging global technological advancements. The device's capabilities extend beyond traditional testing methods, offering on-site verification that can inform immediate safety decisions and remediation actions. This approach represents a shift toward more responsive, accessible testing methodologies that can be deployed across diverse operational environments and emergency scenarios.